BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines ABRAXANE (nab-paclitaxel by Year
ABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M)
BeOne Medicines ABRAXANE (nab-paclitaxel: $0M in FY2021, down 100.0% from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
Source: Form 10-K (filed 2022-02-28) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | -100.0% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 17.8 | -84.0% | Form 10-K (filed 2022-02-28) ↗ |
| FY2019 | Dec 31, 2019 | 111 | +56.3% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 71.2 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines ABRAXANE (nab-paclitaxel ($M), annual FY2018–FY2021 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-abraxane
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.